Clinical trial
Polyglutamate Camptothecin in Treating Patients With Advanced Cancer
NCT00059917 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00059917 |
|---|---|
| Title | Polyglutamate Camptothecin in Treating Patients With Advanced Cancer |
| Official title | Phase I Study of CT-2106 in Patients With Advanced Malignancy |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | polyglutamate camptothecin |
| Start date | Jan 1, 2003 |
| Completion | May 1, 2005 |
| First posted | May 7, 2003 |
| Last update posted | May 30, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: